Skip to main content
OpenTrials

Clinical trial condition

Meningococcal Infections

Explore clinical trials studying Meningococcal Infections. Study availability and eligibility vary by location and protocol.

216 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Meningococcal Infections trial results

Completed

Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects

NCT01641042

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Antioch, California, United States
  • GSK Investigational Site Daly City, California, United States
  • GSK Investigational Site Fremont, California, United States
  • GSK Investigational Site Hayward, California, United States
View all 16 locations
View Trial Details
Completed

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

NCT00657709

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +12 more
Locations
  • Grässl Hall in Tirol, Austria
  • Häckel Kirchdorf, Austria
  • Prieler Neufeld A.d. Leitha, Austria
  • Maurer Salzburg, Austria
View all 66 locations
View Trial Details
Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age

NCT01767376

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +14 more
Locations
  • GSK Investigational Site Santo Domingo, Distrito Nacional, Dominican Republic
  • GSK Investigational Site Kehl, Baden-Wurttemberg, Germany
  • GSK Investigational Site Tuttlingen, Baden-Wurttemberg, Germany
  • GSK Investigational Site Bindlach, Bavaria, Germany
View all 15 locations
View Trial Details
Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

NCT00944034

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +13 more
Locations
  • Avenue Albert 1er 185, 5000 Namur, Belgium
  • Avenue Hippocrate 10, 1200 Brussels, Belgium
  • Laarbeeklaan 101, 1090 Brussels, Belgium
  • Lindendreef 1, 2020 Antwerpen, Belgium
View all 72 locations
View Trial Details
Completed

Testing the Use of Prompts to Increase Adolescent Immunization Rates

NCT01984125

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Bordetella Infections, +17 more
Locations
  • University of Arkansas - Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Wilmington Hospital Health Center Wilmington, Delaware, United States
  • University of Florida Gainesville, Florida, United States
  • Children's Memorial Hospital - Northwestern University Chicago, Illinois, United States
View all 22 locations
View Trial Details
Completed

Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

NCT01434680

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +13 more
Locations
  • NZOZ Bioscience Sp zoo Ul Czerkaska, Bydgoszcz, Poland
  • Department Infection Disease ZOZ Dept Infection Disease ZOZ, Debica, Poland
  • Centrum Medyczne Graniczna Sp zoo Ul Graniczna 45, Katowice, Poland
  • NZOZ HIPOKRATES IIspzoo Ul Strzelecka 2, Krakow, Poland
View Trial Details

Related conditions